<DOC>
	<DOCNO>NCT00901927</DOCNO>
	<brief_summary>The goal clinical research study learn combination bendamustine hydrochloride , mitoxantrone , rituximab help control follicular lymphoma . The safety drug combination also study .</brief_summary>
	<brief_title>Bendamustine , Mitoxantrone , Rituximab ( BMR ) Patients With Untreated High Risk Follicular Lymphoma</brief_title>
	<detailed_description>The Study Drugs : Bendamustine design damage destroy DNA ( genetic material ) cancer cell . Mitoxantrone design stop cancer cell make DNA , may stop cell make cell . Rituximab design attach lymphoma cell , may cause die . Study Drug Administration : If find eligible take part study , receive study drug 28-day `` cycle . '' On Days 1 2 cycle , receive bendamustine needle vein 30-60 minute . On Day 1 cycle , receive rituximab vein several hour , depend well tolerate . Usually , first dose rituximab give 6-8 hour . If tolerate first dose well , receive next dos 4 hour . On Day 2 cycle , receive mitoxantrone vein 15 minute . Study Visits : At every study visit ( Days 1 , 8 , 15 , 22 cycle ) , vital sign measure . You ask experienced side effect list drug may take . The measurement vital sign Days 8 , 15 , 22 cycle may do personal doctor , result send study staff . On Day 1 cycle , follow test procedure perform : - You physical exam , include measurement weight . - Blood ( 1-2 teaspoon ) draw routine test . - You performance status evaluation . On Days 8 , 15 , 22 cycle , blood ( 1 teaspoon ) drawn routine test . These test may perform personal doctor , result send study staff . At end Cycle 3 , positron emission tomography ( PET ) scan and/or CT scan check status disease . If bone marrow show lymphoma beginning study , additional bone marrow aspiration biopsy disease go away study . This check status disease . If time doctor think necessary , extra blood urine collect routine test . Length Study Participation : You may receive 6 cycle ( 6 month ) study treatment . If disease get bad intolerable side effect occur , take study treatment early . End-of-Study Visit : At 30-40 day last dose study drug , end-of-study visit . At visit , follow test procedure perform : - You physical exam , include measurement vital sign weight . - You performance status evaluation . - Blood ( 1-2 teaspoon ) draw routine test . - You CT PET scan check status disease . - You ask experienced side effect list drug may take . Long-Term Follow-Up : Every 3 month 2 year study treatment end , follow-up visit . If 2 year body show sign cancer , follow-up visit every 6 month . These follow-up test consider routine care . The following test procedure perform visit : - You performance status evaluation . - Blood ( 1-2 teaspoon ) draw routine test . - You ask whether receive new treatment disease . - You CT PET scan check status disease . - The study doctor check result scan test may routine care . The study doctor also check result physical exam may . This investigational study . All 3 study drug commercially available . Rituximab FDA approve treat follicular lymphoma . Mitoxantrone FDA approve use combination certain type leukemia . Bendamustine FDA approve treat chronic lymphocytic leukemia . The combination rituximab , mitoxantrone , bendamustine FDA approve treat follicular lymphoma . At time , use research . Up 37 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Age &gt; 18 year time signing informed consent form . 2 . Able adhere study visit schedule protocol requirement . 3 . Untreated grade 1 , 2 , 3a follicular nonHodgkin 's lymphoma . 4 . At least one measurable lesion accord International Working Group Criteria Response , great 1.5cm . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 study entry . 6 . Laboratory test result within range : Absolute neutrophil count &gt; /=1.5 x 10^9/L ; Platelet count &gt; /=100 x 10^9/L ; Serum creatinine &lt; /= 2.0 mg/dL ; Total bilirubin &lt; /= 1.5 mg/dL ; AST ( SGOT ) ALT ( SGPT ) &lt; /= 2 x upper limit normal ( ULN ) &lt; /= 5 x ULN hepatic metastasis present . 7 . Disease free prior malignancy least 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma insitu cervix breast . 8 . Have high risk FLIPI score , define FLIPI score &gt; /= 3 . 9 . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 milliInternational unit ( mIU ) /mL within 10 14 day prior study entry . 10 . An ejection fraction &gt; /= 50 % documented cardiac function study . 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Use prior chemotherapy follicular lymphoma . 5 . Known hypersensitivity Bendamustine , mitoxantrone , mannitol . 6 . A history congestive heart failure . 7 . Any prior use bendamustine mitoxantrone . 8 . Concurrent use anticancer agent experimental treatment . 9 . Known positive HIV infectious hepatitis type B C. 10 . Creatinine clearance le 40 ml/min . 11 . A known history hepatic insufficiency ( patient history fulminate hepatic failure , hepatic encephalopathy , cirrhosis , autoimmune hepatitis ) . 12 . Any history grade 3b follicular lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Untreated High Risk Follicular Lymphoma</keyword>
	<keyword>Bendamustine hydrochloride</keyword>
	<keyword>Bendamustine HCI</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>CEP-18083</keyword>
	<keyword>SDX-105</keyword>
	<keyword>Treanda</keyword>
	<keyword>Mitoxantrone</keyword>
	<keyword>Novantrone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
</DOC>